Bispecific single chain Fv antibody molecules and methods of use thereof
View Patent ↗Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
1. A bispecific antibody comprising a first antibody joined to a second antibody, wherein:
said first antibody comprises a VH domain comprising the C6B1D2 VH CDR1 sequence SYWIA (SEQ ID NO:59), the C6B1D2 VH CDR2 sequence LIYPGDSDTKYSPSFQG (SEQ ID NO:60), and the C6B1D2 VH CDR3 sequence HDVGYCTDRTCAKWPEWLGV (SEQ ID NO:61); and a VL domain comprising C6B1D2 VL CDR1 sequence SGSSSNIGNNYVS (SEQ ID NO:62), the C6B1D2 VL CDR2 sequence DHTNRPA (SEQ ID NO:63), and the C6B1D2 VL CDR3 sequence ASWDYTLSGWV (SEQ ID NO:64); and
said second antibody comprises three VH CDRs and three VL CDRs of an antibody selected from the group consisting of HER3.F4 (SEQ ID NO:2), HER3.H1 (SEQ ID NO:3), HER3.H3 (SEQ ID NO:4), HER3.E12 (SEQ ID NO:5), HER3.B12 (SEQ ID NO:6), EGFR.E12 (SEQ ID NO:7), EGFR.C10 (SEQ ID NO:8), EGFR.B11 (SEQ ID NO:9), EGFR.E8 (SEQ ID NO:10), HER4.B6 (SEQ ID NO:19), and C6B1D2 (SEQ ID NOs:52 and 57).
2. The bispecific antibody of claim 1 , wherein said second antibody comprises:
a VH domain comprising the HER3.H3 VH CDR1 sequence SYWMS (SEQ ID NO:65), the HER3.H3 VH CDR2 sequence NINRDGSASYYVDSVKG (SEQ ID NO:66), and the HER3.H3 VH CDR3 sequence DRGVGYFDL (SEQ ID NO:67); and
a VL domain comprising the HER3.H3 VL CDR1 sequence TGTSSDVGGYNFVS (SEQ ID NO:68), the HER3.H3 VL CDR2 sequence DVSDRPS (SEQ ID NO:69), and the HER3.H3 VL CDR3 sequence SSYGSSSTHVI (SEQ ID NO:70).
3. The bispecific antibody of claim 2 , wherein said first antibody comprises:
a VH domain comprising a C6B1D2 framework 1 region comprising the sequence QVQLVQSGAEVKKPGESLKISCKGSGYSFT (SEQ ID NO:71) or QVQLLQSGAEVKKPGESLKISCKGSGYSFT (SEQ ID NO:72), a C6B1D2 framework 2 region comprising the sequence WVRQMPGKGLEYMG (SEQ ID NO:73), a C6B1D2 framework 3 region comprising the sequence QVTISVDKSVSTAYLQWSSLKPSDSAVYFCAR (SEQ ID NO:74), and a C6B1D2 framework 4 region comprising the sequence WGQGTLVTVSS (SEQ ID NO:75); and
a VL domain comprising a C6B1D2 framework 1 region comprising the sequence QSVLTQPPSVSAAPGQKVTISC (SEQ ID NO:76) or ESVLTQPPSVSAAPGQKVTISC (SEQ ID NO:77), a C6B1D2 framework 2 region comprising the sequence WYQQLPGTAPKLLIY (SEQ ID NO:78), a C6B1D2 framework 3 region comprising the sequence GVPDRFSGSKSGTSASLAISGFRSEDEADYYC (SEQ ID NO:79); and a C6B1D2 framework 4 region comprising the sequence FGGGTKVTVLG (SEQ ID NO:80) or FGGGTKLTVLG (SEQ ID NO:81).
4. The bispecific antibody of claim 2 , wherein said first antibody is a attached to said second antibody by a linker.
5. The bispecific antibody of claim 2 , wherein said first antibody is a single chain antibody and said second antibody is a single chain antibody.
6. The bispecific antibody of claim 2 , wherein said first antibody is a single chain Fv antibody.
7. The bispecific antibody of claim 2 , wherein said second antibody is a single chain FV antibody.
8. The bispecific antibody of claim 5 , wherein said first antibody is a single chain Fv antibody and said second antibody is a single chain Fv.
9. The bispecific antibody of claim 8 , wherein said first antibody is attached to said second antibody by a peptide linker.
10. A composition comprising the bispecific antibody according to any one of claims 1 - 4 , 7 - 8 , and 9 and a pharmaceutically acceptable carrier.
11. The composition of claim 10 , wherein said composition is formulated for injection.
12. The composition of claim 11 , wherein said composition is formulated for intravenous injection.
13. The composition of claim 11 , wherein said composition is in unit dosage form.
14. The composition of claim 12 , wherein said composition is in unit dosage form.
15. A method for treating a cancer that overexpresses HER2 and/or HER3 proteins, said method comprising administering to a patient in need thereof a therapeutically effective amount of the bispecific antibody comprising a first single chain Fv antibody that binds HER2/neu and a second single chain Fv antibody that binds HER3, wherein said first antibody comprises a heavy chain variable domain comprising all three VH CDRs of the antibody B1D2 VH domain (SEQ ID NO:42) and a light chain variable (VL) domain comprising all three VL CDRs of the antibody B1D2 VL domain (SEQ ID NO:47), and said second antibody comprises a heavy chain variable domain comprising all three VH CDRs of antibody HER3.H3 (SEQ ID NO:4) and a light chain variable (VL) domain comprising all three CDRs of antibody HER3.H3 (SEQ ID NO:4).
16. The method of claim 15 , wherein the cancer is selected from the group consisting of breast, colon, ovarian, endometrial, gastric, pancreatic, prostate, and salivary gland cancer.
17. The method of claim 16 , wherein the cancer is breast cancer or gastric cancer.